Novavax announced that the World Health Organization – WHO – has issued an updated Emergency Use Listing for Nuvaxovid COVID-19 vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 as a primary series of two doses in adolescents aged 12 through 17 and as a booster in adults aged 18 and older.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVAX: